Regeneron
4 stories
-
healthUnderstanding Chronic Spontaneous Urticaria
A clinical overview of chronic spontaneous urticaria, its link to type 2 inflammation, and evolving biologic treatment options.
-
healthRegeneron Leader: Europe's Clinical Trials at a Crossroads
Muriel O'Byrne of Regeneron discusses regulatory bottlenecks, genetic breakthroughs, and leadership in clinical trials.
-
healthWhite House Secures Drug Pricing Deal with Regeneron
The White House is set to announce a drug pricing agreement with pharmaceutical company Regeneron, finalizing deals with all major drug manufacturers targeted by the administration.
-
healthFDA Approves First Gene Therapy for Inherited Deafness
Regeneron's Otarmeni receives FDA approval, marking a significant advancement in treating OTOF gene-related hearing loss in children and adults.